| Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells S Spranger, RM Spaapen, Y Zha, J Williams, Y Meng, TT Ha, TF Gajewski Science translational medicine 5 (200), 200ra116-200ra116, 2013 | 1796 | 2013 |
| Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment TF Gajewski, SR Woo, Y Zha, R Spaapen, Y Zheng, L Corrales, ... Current opinion in immunology 25 (2), 268-276, 2013 | 451 | 2013 |
| Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma T Scanu, RM Spaapen, JM Bakker, CB Pratap, L Wu, I Hofland, A Broeks, ... Cell host & microbe 17 (6), 763-774, 2015 | 249 | 2015 |
| An ER-associated pathway defines endosomal architecture for controlled cargo transport MLM Jongsma, I Berlin, RHM Wijdeven, L Janssen, GMC Janssen, ... Cell 166 (1), 152-166, 2016 | 235 | 2016 |
| Functional characteristics of the high affinity IgG receptor, FcγRI CE van der Poel, RM Spaapen, JGJ van de Winkel, JHW Leusen The Journal of Immunology 186 (5), 2699-2704, 2011 | 207 | 2011 |
| TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the endoplasmic reticulum G Hassink, M Kikkert, S VOORDEN, SJ Lee, R Spaapen, T LAAR, ... Biochemical Journal 388 (2), 647-655, 2005 | 204 | 2005 |
| Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment TF Gajewski, M Fuertes, R Spaapen, Y Zheng, J Kline Current opinion in immunology 23 (2), 286-292, 2011 | 170 | 2011 |
| The regulatory network behind MHC class I expression MLM Jongsma, G Guarda, RM Spaapen Molecular immunology 113, 16-21, 2019 | 136 | 2019 |
| The role of glycosphingolipids in immune cell functions T Zhang, AA de Waard, M Wuhrer, RM Spaapen Frontiers in immunology 10, 428186, 2019 | 127 | 2019 |
| Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature RM Spaapen, MYK Leung, MB Fuertes, JP Kline, L Zhang, Y Zheng, ... The Journal of Immunology 193 (8), 4254-4260, 2014 | 88 | 2014 |
| Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis RM Spaapen, HM Lokhorst, K van den Oudenalder, BE Otterud, H Dolstra, ... The Journal of experimental medicine 205 (12), 2863-2872, 2008 | 82 | 2008 |
| Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes C Hassan, MGD Kester, G Oudgenoeg, AH de Ru, GMC Janssen, ... Journal of Proteomics 109, 240-244, 2014 | 77 | 2014 |
| The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses MLM Jongsma, AA de Waard, M Raaben, T Zhang, B Cabukusta, ... Immunity 54 (1), 132-150. e9, 2021 | 72 | 2021 |
| Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing BW MacNabb, X Chen, S Tumuluru, J Godfrey, DN Kasal, J Yu, ... Immunity 55 (6), 982-997. e8, 2022 | 62 | 2022 |
| Altered peptide ligands revisited: Vaccine design through chemically modified HLA-A2–restricted T cell epitopes R Hoppes, R Oostvogels, JJ Luimstra, K Wals, M Toebes, L Bies, ... The Journal of Immunology 193 (10), 4803-4813, 2014 | 59 | 2014 |
| A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect H Rozemuller, E van der Spek, LH Bogers-Boer, MC Zwart, V Verweij, ... haematologica 93 (7), 1049-1057, 2008 | 56 | 2008 |
| Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy Y Zheng, Y Zha, RM Spaapen, R Mathew, K Barr, A Bendelac, ... Molecular immunology 55 (3-4), 283-291, 2013 | 50 | 2013 |
| Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile R De Groot, MM Van Loenen, A Guislain, BP Nicolet, ... Oncoimmunology 8 (11), e1648170, 2019 | 47 | 2019 |
| Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease R Spaapen, T Mutis Best Practice & Research Clinical Haematology 21 (3), 543-557, 2008 | 47 | 2008 |
| Rebuilding Human Leukocyte Antigen Class II–Restricted Minor Histocompatibility Antigen Specificity in Recall Antigen-Specific T Cells by Adoptive T Cell Receptor Transfer … R Spaapen, K Van Den Oudenalder, R Ivanov, A Bloem, H Lokhorst, ... Clinical cancer research 13 (13), 4009-4015, 2007 | 47 | 2007 |
Jacques NeefjesHoogleraar cell biologie en immunologie, Leiden UniversiteitVerified email at nki.nl
